Hi WFW Pitch Deck Teardowns,
I’m reaching out to introduce CryoSage Diagnostics, an early-stage biotech developing a polymer-based biomarker preservation technology designed to reduce reliance on cold-chain logistics in diagnostic workflows.
Today, a significant portion of diagnostic samples are compromised due to cold-chain failures, particularly in field, mobile, and low-resource settings. CryoSage’s core technology, CryoMatrix™, aims to stabilise DNA, RNA, and protein biomarkers at ambient temperatures by mimicking cryoprotective mechanisms observed in extremophiles.
At proof-of-concept stage, we’ve demonstrated >95% biomarker integrity retention over 45 days at 25°C in controlled lab settings with university and hospital collaborators. The technology is currently pre-product and pre-regulatory, with key risks remaining around biological breadth, scale-up, and real-world handling conditions.
We’re pre-revenue and in early customer discovery with diagnostic labs and research groups exploring use cases where refrigeration is unreliable or costly.
We’re raising a $2.5M seed round to complete material optimisation, expand validation across additional biomarker classes, and advance IP coverage.
Short overview below.
Happy to share early data or discuss technical constraints if helpful.
Best,
Dr. Elias Marin
Founder & CEO, CryoSage Diagnostics
CryoSage Diagnostics
Polymer-based technology intended to preserve biological samples at ambient temperatures without refrigeration.
Problem:
Diagnostic systems rely heavily on cold-chain logistics to maintain sample integrity. In field settings and low-resource environments, cold-chain failure rates are high, leading to sample degradation, retesting, and unreliable results.
Solution:
CryoMatrix™, a proprietary polymer blend designed to stabilise biological molecules (DNA, RNA, proteins) at ambient temperatures by inducing a vitrified, low-mobility state.
Technical Status & Feasibility:
- Proof-of-concept validation completed in controlled lab environments
- >95% biomarker integrity retained over 45 days at 25°C (select biomarker classes)
- Early-stage synthetic cryoprotectant chemistry inspired by extremophile biology
- 1 patent filed covering polymer formulation and process method
- Key open risks: biomarker breadth, long-term stability, handling variability, and scale-up
Customer Discovery:
- Research MoUs with university and hospital partners
- Exploratory conversations with diagnostic labs and mobile testing providers
Market Context:
- ~$7B global diagnostic consumables market
- Initial relevance in field diagnostics and low-resource settings
- Longer-term applicability to pharma logistics remains unvalidated
Team:
- Dr. Elias Marin (CEO): PhD Biochemistry, formerly Thermo Fisher Cryo Systems
- Dr. Olivia Chen (CTO): Biomaterial synthesis, ex-CSIRO
- James Leung (Operations): Supply chain and medtech manufacturing, ex-Fisher & Paykel
Raise
$2.5M USD seed to optimize CryoMatrix™ formulation, expand biological validation, and strengthen IP coverage.
Quick Navigation:
Back to 
CryoSage Diagnostics — WFW VC Teardown #06
🚨 Disclaimers: All startup companies, business models, products and founders described in VC Teardowns are fictional and created solely for educational purposes. Any resemblance to actual companies, persons or events - past, present or future - is purely coincidental. The opinion of each participating VC reflects their individual perspective and does not represent their firm as a whole. A teardown should not be treated as a universal rulebook. Founders are encouraged to engage investors early and build relationships - early conversations are often exploratory, not evaluative.